FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation
FB-HRS, LLC today announced the US Food and Drug Administration has cleared an Investigational New Drug (IND) application to initiate its Clinical Trial of FBHRS001, a fixed dose combination (FDC) of two drugs, for the treatment of atrial fibrillation. This FDC product is being evaluated for the improved safety and efficacy, in comparison to existing drugs on the market.
View full press release